Slight hiatus in content on this site

Your Sitemaster apologizes for the hiatus in delivery of new content over the past few days. He has been dealing with a personal family issue and hopes to be able to “get things back to normal” over the next 2-3 days.

Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …

Uptake of robot-assisted radical prostatectomy in the Netherlands

There is an interesting article just published in Social Science & Medicine that addresses the social, “emotive”, and other drivers for uptake of da Vinci robot-assisted radical prostatectomy over the past few years in the Netherlands. … READ MORE …

FDA has questions about Ablatherm HIFU device

According to a report on the Bloomberg News web site, the FDA’s reviewers appear to be less than enthusiastic about the effectiveness and safety data submitted by EDAP TMS to support approval of the Ablatherm device for use of high-intensity focused ultrasound (HIFU) for the treatment of low-risk forms of prostate cancer. … READ MORE …

Robot-assisted versus open radical cystectomy: no clear signs of immediate benefit

Many readers of this blog have probably heard or read the reports like this one on the CBS Evening News or this one on the Reuters web site that there were no significant short-term (perioperative) differences in outcome between robot-assisted radical cystectomy (complete removal of the bladder) and the older open surgical procedure. … READ MORE …

NICE approves coverage for enzalutamide by NHS

The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …

The potential promise of BLZ-100 or “tumor paint”

There has been a lot of media interest in the past couple of weeks in a new technology that may be very helpful in enhancing the visibility of cancerous tissues and the ability to differentiate visually between cancerous and healthy tissue. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers